MeiraGTX: Asset Purchase Agreement, AAV-RPGR Collaboration for up to $415 m

 - MeiraGTx enters into an Asset Purchase Agreement related to botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) for a total of up to $415 million

- MeiraGTx to receive $130 million in upfront and near-term milestone payments as part of the agreement

- MeiraGTx to receive up to an additional $285 million upon first commercial sales of bota-vec in U.S. and EU and manufacturing technology transfer

https://www.globenewswire.com/news-release/2023/12/21/2799891/0/en/MeiraGTx-Announces-Asset-Purchase-Agreement-Involving-its-AAV-RPGR-Collaboration-for-up-to-415-million.html